Page 147 - The clinical aspects and management of chronic migraine Judith Anne Pijpers
P. 147

62. Zhang X, Strassman AM, Novack V, Brin MF, Burstein R. Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle? Cephalalgia. 2016;0(0):1-12. doi:10.1177/0333102416636843
63. Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M. Long-Distance Retrograde Effects of Botulinum Neurotoxin A. J Neurosci. 2008;28(14):3689-3696. doi:10.1523/JNEUROSCI.0375-08.2008
64. Lawrence GW, Ovsepian S V., Wang J, Aoki KR, Dolly JO. Extravesicular intraneuronal migration of internalized botulinum neurotoxins without detectable inhibition of distal neurotransmission. Biochem J. 2012;441(1):443-452. doi:10.1042/BJ20111117
65. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):804-814. doi:10.1177/0333102410364676
66. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804-814. doi:10.1177/0333102410364677
67. Blumenfeld AM, Aurora SK, Laranjo K, Papapetropoulos S. Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine. BMC Neurol. 2015;15(1):100. doi:10.1186/s12883-015-0353-x
68. Bigal ME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015;79(6):886-895. doi:10.1111/bcp.12591
69. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017;377(22):2113-2122. doi:10.1212/WNL.0000000000002801
70. Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425-434. doi:10.1016/S1474-4422(17)30083-2
71. Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211-e2221. doi:10.1212/WNL.0000000000006640
72. Deen M, Correnti E, Kamm K, et al. Blocking CGRP in migraine patients – a review of pros and cons. J Headache Pain. 2017;18(1):96. doi:10.1186/s10194-017-0807-1
73. Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6. doi:10.1186/s10194-018-0955-y
74. Olesen J,Tfelt-Hansen P. Licence for Botox in so-called chronic migraine. Lancet. 2010;376(9755):1825- 1826. doi:10.1016/S0140-6736(10)62165-4
75. Solomon S. OnabotulinumtoxinA for treatment of chronic migraine: the unblinding problem. Headache. 2013;53(5):824-826. doi:10.1111/head.12065
76. Finniss DG, Kaptchuk TJ, Miller F, Benedetti F. Biological, clinical, and ethical advances of placebo effects. Lancet. 2010;375(9715):686-695. doi:10.1016/S0140-6736(09)61706-2
77. Kam-hansen S, Jakubowski M, Kelley JM, et al. Altered Placebo and Drug Labeling Changes the Outcome of Episodic Migraine Attacks. Sci Transl Med. 2014;8(6):1-8.
78. Solomon S. A review of mechanisms of response to pain therapy: Why voodoo works. Headache. 2002;42(7):656-662. doi:10.1046/j.1526-4610.2002.02155.x
79. Zunhammer M, Bingel U, Wager TD. Placebo Effects on the Neurologic Pain Signature. JAMA Neurol. 2018;75(11):1321. doi:10.1001/jamaneurol.2018.2017
7
Summary and general discussion
145
 













































































   145   146   147   148   149